Targeting PD-1/PD-L1 in Advanced Thyroid Cancer: Therapeutic Efficacy, Predictive Biomarkers, and Clinical Challenges
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Brieflands
Abstract
Context: Thyroid cancer is the most common endocrine malignancy and generally has a favorable prognosis. However, aggressive subtypes and advanced radioactive iodine-refractory disease remain associated with limited therapeutic options and poor outcomes. The programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway has emerged as an important regulator of immune escape and a potential therapeutic target in advanced thyroid cancer. Evidence Acquisition: This narrative review examines evidence on PD-1/PD-L1 pathway biology, interactions between this pathway and the thyroid tumor immune microenvironment, molecular regulation, clinical significance, therapeutic applications, mechanisms of resistance, and future perspectives. Results: The PD-1/PD-L1 axis promotes immune evasion by suppressing T-cell activation, driving T-cell exhaustion, and establishing an immunosuppressive tumor microenvironment. PD-L1 expression is detectable across thyroid cancer subtypes, with the highest frequency reported in poorly differentiated and anaplastic carcinomas. The BRAF V600E mutation, mitogen-activated protein kinase pathway activation, PI3K/AKT signaling, inflammatory cytokines, and hypoxia contribute to PD-L1 regulation. Clinical responses to checkpoint blockade are heterogeneous, and the absence of validated predictive biomarkers remains a major obstacle. PD-L1 expression alone is insufficient for reliable patient selection. Conclusions: Targeting the PD-1/PD-L1 pathway offers therapeutic potential for selected patients with advanced thyroid cancer. Further progress requires integrated biomarker strategies that combine tumor genomics, immune profiling, and microenvironmental characteristics, as well as a better understanding of resistance mechanisms and validation in thyroid-specific clinical trials.